| Zacks Company Profile for Vir Biotechnology, Inc. (VIR : NSDQ) |
|
|
| |
| • Company Description |
| Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. Vir Biotechnology Inc. is based in San Francisco, United States.
Number of Employees: 367 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $8.69 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,837,197 shares |
| Shares Outstanding: 168.65 (millions) |
| Market Capitalization: $1,465.59 (millions) |
| Beta: 1.62 |
| 52 Week High: $11.66 |
| 52 Week Low: $4.16 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-12.04% |
-12.69% |
| 12 Week |
-14.93% |
-17.26% |
| Year To Date |
44.11% |
43.12% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
1800 OWENS STREET SUITE 900
-
SAN FRANCISCO,CA 94158
USA |
ph: 415-906-4324
fax: - |
ir@vir.bio |
http://www.vir.bio |
|
|
| |
| • General Corporate Information |
Officers
Marianne De Backer - Chief Executive Officer and Director
Vicki Sato - Chairman
Jason O'Byrne - Executive Vice President and Chief Financial Offic
Brent Sabatini - Senior Vice President and Chief Accounting Officer
Norbert Bischofberger - Director
|
|
Peer Information
Vir Biotechnology, Inc. (CORR.)
Vir Biotechnology, Inc. (RSPI)
Vir Biotechnology, Inc. (CGXP)
Vir Biotechnology, Inc. (BGEN)
Vir Biotechnology, Inc. (GTBP)
Vir Biotechnology, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 92764N102
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/05/26
|
|
Share - Related Items
Shares Outstanding: 168.65
Most Recent Split Date: (:1)
Beta: 1.62
Market Capitalization: $1,465.59 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.76 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-1.81 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 4.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: 40.37% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/05/26 |
|
|
|
| |
